Kringle Pharma（4884）株式概要クリングルファーマ株式会社は日本で難病治療薬の研究開発を行っている。 詳細4884 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析収益が 100 万ドル未満 ( ¥73M )JP市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去5年間で収益は年間26%減少しました。 意味のある時価総額がありません ( ¥3B )すべてのリスクチェックを見る4884 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueJP¥Current PriceJP¥393.0019.5k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-920m504m2016201920222025202620282031Revenue JP¥5.6mEarnings JP¥1.0mAdvancedSet Fair ValueView all narrativesKringle Pharma, Inc. 競合他社Solasia Pharma K.KSymbol: TSE:4597Market cap: JP¥7.1bD. Western Therapeutics InstituteSymbol: TSE:4576Market cap: JP¥4.3bTransgenic GroupSymbol: TSE:2342Market cap: JP¥4.1bPerseus ProteomicsSymbol: TSE:4882Market cap: JP¥2.3b価格と性能株価の高値、安値、推移の概要Kringle Pharma過去の株価現在の株価JP¥393.0052週高値JP¥1,125.0052週安値JP¥365.00ベータ0.361ヶ月の変化-18.80%3ヶ月変化-0.51%1年変化-55.34%3年間の変化-54.46%5年間の変化-52.71%IPOからの変化-67.33%最新ニュースReported Earnings • May 13Second quarter 2026 earnings released: JP¥42.92 loss per share (vs JP¥43.84 loss in 2Q 2025)Second quarter 2026 results: JP¥42.92 loss per share. Net loss: JP¥314.2m (loss widened 5.0% from 2Q 2025).New Risk • Apr 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥755m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥755m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (JP¥73m revenue, or US$457k). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (JP¥3.70b market cap, or US$23.3m).分析記事 • Apr 01Is Kringle Pharma (TSE:4884) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...New Risk • Feb 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥755m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥755m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (JP¥73m revenue, or US$474k). Minor Risk Market cap is less than US$100m (JP¥2.96b market cap, or US$19.3m).Reported Earnings • Feb 10First quarter 2026 earnings released: JP¥28.08 loss per share (vs JP¥31.23 loss in 1Q 2025)First quarter 2026 results: JP¥28.08 loss per share (improved from JP¥31.23 loss in 1Q 2025). Net loss: JP¥201.0m (loss narrowed 5.5% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.Reported Earnings • Dec 25Full year 2025 earnings released: JP¥134 loss per share (vs JP¥118 loss in FY 2024)Full year 2025 results: JP¥134 loss per share (further deteriorated from JP¥118 loss in FY 2024). Net loss: JP¥916.0m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.最新情報をもっと見るRecent updatesReported Earnings • May 13Second quarter 2026 earnings released: JP¥42.92 loss per share (vs JP¥43.84 loss in 2Q 2025)Second quarter 2026 results: JP¥42.92 loss per share. Net loss: JP¥314.2m (loss widened 5.0% from 2Q 2025).New Risk • Apr 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥755m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥755m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (JP¥73m revenue, or US$457k). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (JP¥3.70b market cap, or US$23.3m).分析記事 • Apr 01Is Kringle Pharma (TSE:4884) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...New Risk • Feb 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥755m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥755m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (JP¥73m revenue, or US$474k). Minor Risk Market cap is less than US$100m (JP¥2.96b market cap, or US$19.3m).Reported Earnings • Feb 10First quarter 2026 earnings released: JP¥28.08 loss per share (vs JP¥31.23 loss in 1Q 2025)First quarter 2026 results: JP¥28.08 loss per share (improved from JP¥31.23 loss in 1Q 2025). Net loss: JP¥201.0m (loss narrowed 5.5% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.Reported Earnings • Dec 25Full year 2025 earnings released: JP¥134 loss per share (vs JP¥118 loss in FY 2024)Full year 2025 results: JP¥134 loss per share (further deteriorated from JP¥118 loss in FY 2024). Net loss: JP¥916.0m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.お知らせ • Dec 02+ 1 more updateKringle Pharma, Inc. to Report Q1, 2026 Results on Feb 09, 2026Kringle Pharma, Inc. announced that they will report Q1, 2026 results on Feb 09, 2026Reported Earnings • Nov 15Full year 2025 earnings released: JP¥134 loss per share (vs JP¥118 loss in FY 2024)Full year 2025 results: JP¥134 loss per share (further deteriorated from JP¥118 loss in FY 2024). Net loss: JP¥916.0m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • Nov 12Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2025Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2025.お知らせ • Aug 29Kringle Pharma, Inc. to Report Fiscal Year 2025 Results on Nov 12, 2025Kringle Pharma, Inc. announced that they will report fiscal year 2025 results on Nov 12, 2025Reported Earnings • Aug 10Third quarter 2025 earnings released: JP¥33.20 loss per share (vs JP¥22.96 loss in 3Q 2024)Third quarter 2025 results: JP¥33.20 loss per share (further deteriorated from JP¥22.96 loss in 3Q 2024). Net loss: JP¥227.0m (loss widened 49% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Aug 02Kringle Pharma, Inc. announced that it has received ¥1.003 million in funding from Evolution Capital Management LLCOn August 1, 2025, Kringle Pharma, Inc. closed the transaction.お知らせ • Jun 27Kringle Pharma, Inc. to Report Q3, 2025 Results on Aug 08, 2025Kringle Pharma, Inc. announced that they will report Q3, 2025 results on Aug 08, 2025New Risk • Jun 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 35% per year over the past 5 years. Revenue is less than US$1m (JP¥72m revenue, or US$496k). Minor Risk Market cap is less than US$100m (JP¥6.89b market cap, or US$47.5m).Reported Earnings • May 14Second quarter 2025 earnings released: JP¥43.84 loss per share (vs JP¥30.66 loss in 2Q 2024)Second quarter 2025 results: JP¥43.84 loss per share (further deteriorated from JP¥30.66 loss in 2Q 2024). Net loss: JP¥299.3m (loss widened 52% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.Reported Earnings • Feb 08First quarter 2025 earnings released: JP¥31.13 loss per share (vs JP¥29.45 loss in 1Q 2024)First quarter 2025 results: JP¥31.13 loss per share (further deteriorated from JP¥29.45 loss in 1Q 2024). Net loss: JP¥212.0m (loss widened 25% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.New Risk • Jan 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (JP¥80m revenue, or US$507k). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (JP¥6.92b market cap, or US$43.9m).お知らせ • Jan 03+ 1 more updateKringle Pharma, Inc. to Report Q1, 2025 Results on Feb 07, 2025Kringle Pharma, Inc. announced that they will report Q1, 2025 results on Feb 07, 2025Reported Earnings • Dec 28Full year 2024 earnings released: JP¥118 loss per share (vs JP¥158 loss in FY 2023)Full year 2024 results: JP¥118 loss per share (improved from JP¥158 loss in FY 2023). Net loss: JP¥756.0m (loss narrowed 12% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.お知らせ • Nov 26Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2025Kringle Pharma, Inc. provided Non-consolidated earnings guidance for the fiscal year ending September 30, 2025. For the year, the company expects net sales of JPY 272 million, operating loss of JPY 1,379 million, loss of JPY 1,380 million and basic loss per share of JPY 202.7.分析記事 • Nov 25We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...お知らせ • Nov 13Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024.お知らせ • Aug 29Kringle Pharma, Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024Kringle Pharma, Inc. announced that they will report fiscal year 2024 results on Nov 13, 2024お知らせ • Aug 22Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024Kringle Pharma, Inc. provided Non-consolidated earnings guidance for the fiscal year ending September 30, 2024. For the year, the company expects net sales of JPY 79 million, operating loss of JPY 1,003 million, loss of JPY 942 million and basic loss per share of JPY 147.23.分析記事 • Jun 15Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...Reported Earnings • May 17Second quarter 2024 earnings released: JP¥30.66 loss per share (vs JP¥29.35 loss in 2Q 2023)Second quarter 2024 results: JP¥30.66 loss per share (further deteriorated from JP¥29.35 loss in 2Q 2023). Net loss: JP¥197.0m (loss widened 25% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.分析記事 • Mar 02We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Reported Earnings • Feb 11First quarter 2024 earnings released: JP¥29.45 loss per share (vs JP¥29.18 loss in 1Q 2023)First quarter 2024 results: JP¥29.45 loss per share (further deteriorated from JP¥29.18 loss in 1Q 2023). Net loss: JP¥169.0m (loss widened 7.6% from 1Q 2023).お知らせ • Nov 29Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2024. For the year, the company expects net sales of JPY 272 million, operating loss of JPY 1,133 million, loss of JPY 1,109 million and basic loss per share of JPY 200.86.お知らせ • Nov 27+ 2 more updatesKringle Pharma, Inc. to Report Q1, 2024 Results on Feb 09, 2024Kringle Pharma, Inc. announced that they will report Q1, 2024 results on Feb 09, 2024Reported Earnings • Nov 17Full year 2023 earnings released: JP¥158 loss per share (vs JP¥68.16 loss in FY 2022)Full year 2023 results: JP¥158 loss per share (further deteriorated from JP¥68.16 loss in FY 2022). Net loss: JP¥854.0m (loss widened 158% from FY 2022).New Risk • Oct 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Revenue is less than US$5m (JP¥330m revenue, or US$2.2m). Market cap is less than US$100m (JP¥3.69b market cap, or US$24.6m).お知らせ • Sep 02Kringle Pharma, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023Kringle Pharma, Inc. announced that they will report fiscal year 2023 results on Nov 13, 2023お知らせ • Aug 31Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2023. For the year, the company expects net sales of JPY 68 million, operating loss of JPY 993 million, loss of JPY 955 million and basic loss per share of JPY 177.35.Reported Earnings • Aug 16Third quarter 2023 earnings released: JP¥48.79 loss per share (vs JP¥2.57 profit in 3Q 2022)Third quarter 2023 results: JP¥48.79 loss per share (down from JP¥2.57 profit in 3Q 2022). Revenue: JP¥17.0m (down 80% from 3Q 2022). Net loss: JP¥263.0m (down JP¥276.0m from profit in 3Q 2022).New Risk • Jul 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Revenue is less than US$5m (JP¥398m revenue, or US$2.8m). Market cap is less than US$100m (JP¥4.61b market cap, or US$32.5m).お知らせ • May 30Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2023. For the year, the company expects net sales of JPY 68 million, operating loss of JPY 993 million, loss of JPY 955 million and basic loss per share of JPY 177.44.Reported Earnings • May 19First half 2023 earnings released: JP¥58.52 loss per share (vs JP¥70.08 loss in 1H 2022)First half 2023 results: JP¥58.52 loss per share (improved from JP¥70.08 loss in 1H 2022). Revenue: JP¥34.0m (up 26% from 1H 2022). Net loss: JP¥315.0m (loss narrowed 1.3% from 1H 2022).Reported Earnings • Feb 12First quarter 2023 earnings released: JP¥29.18 loss per share (vs JP¥29.02 loss in 1Q 2022)First quarter 2023 results: JP¥29.18 loss per share (further deteriorated from JP¥29.02 loss in 1Q 2022). Revenue: JP¥17.0m (up 31% from 1Q 2022). Net loss: JP¥157.0m (loss widened 22% from 1Q 2022).お知らせ • Jan 17Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold ScarKringle Pharma, Inc. announced that the first patient was enrolled in a placebo-controlled, double-blind Phase III study to evaluate the efficacy and safety of KP-100LI, the intracordal formulation containing recombinant human HGF, administered in patients with vocal fold scar. The first patient was screened and successfully enrolled for the study at University Hospital, Kyoto Prefectural University of Medicine. As announced in the company news release dated November 24, 2022, the study will be conducted at the five clinical trial sites across Japan including University Hospital, Kyoto Prefectural University of Medicine. Patient enrollment will subsequently start at the other four clinical sites as soon as the contracts and all preparations are completed. The Phase III study has been supported by the Japan Agency for Medical Research and Development (AMED) as its CiCLE program (Project title: Clinical development of recombinant HGF protein for the treatment of refractory fibrosis).お知らせ • Jan 13Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord InjuryKringle Pharma, Inc. provided an update on Phase 3 clinical trial of KP-100IT, the intrathecal formulation of recombinant human HGF, in patients with acute spinal cord injury. KRINGLE was previously expecting to complete patient enrollment by the end of 2022. As of 13 January 2023, however,although more than 90% of the target subjects has been recruited, patient enrollment has not been completed yet primarily due to the prolonged impact of COVID-19 pandemic. KRINGLE continues to enroll patients until it reaches the target number, in close cooperation with the clinical trial sites in order to complete the study as soon as possible. HGF was originally discovered as an endogenous mitogen for mature hepatocytes. Subsequent studiesdemonstrated that HGF exerts multiple biological functions based on its mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic, and angiogenic activities, and facilitates regeneration and protection of a wide variety of organs. HGF exerts neurotrophic effects and enhances neurite outgrowth, and the therapeutic effect of HGF on spinal cord injury has been demonstrated in animal models by Professors Hideyuki Okano and Masaya Nakamura at Keio University School of Medicine. Expectations for HGF as a novel therapeutic agent are increasing for the treatment of spinal cord injury. Spinal cord injury is caused by trauma, leading to a variety of paralytic or painful symptoms. In descending order of incidence, tripping over, traffic accidents and falls from height are the main causes of spinal damage. Recently, due to the rise in the elderly population, tripping over is becoming an increasingly common cause.Reported Earnings • Dec 28Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)Full year 2022 results: JP¥68.16 loss per share. Revenue: JP¥391.0m (up 35% from FY 2021). Net loss: JP¥331.0m (loss widened 10.0% from FY 2021).お知らせ • Dec 28+ 2 more updatesKringle Pharma, Inc. to Report Q1, 2023 Results on Feb 10, 2023Kringle Pharma, Inc. announced that they will report Q1, 2023 results on Feb 10, 2023お知らせ • Dec 01Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023Kringle Pharma, Inc. provided consolidated earnings guidance for year ending September 30, 2023 . For the period, the company expected net sales of JPY 68 million, operating loss of JPY 993 million, loss of parent of JPY 955 million, Basic loss per share of JPY 177.50 per basic share.お知らせ • Nov 24Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold ScarKringle Pharma, Inc. announced the start of Phase III, a placebo-controlled, double-blind clinical study, to confirm the efficacy and safety of recombinant human HGF (KP-100LI) administered in patients with vocal fold scar. KRINGLE aims to develop and commercialize HGF as an innovative therapeutic agent for various fibrotic diseases, focusing on vocal fold scar as the initial target indication. KRINGLE already submitted a Phase III clinical trial application to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, as announced by the KRINGLE news release dated October 24, 2022. Since then, the review process by PMDA was completed and the regulatory clearance was obtained to initiate the Phase III study. KRINGLE and Kyoto Prefectural Public University Corporation (Chairman: Akihiro Kinda) have signed a clinical trial agreement for the Phase III study, and University Hospital, Kyoto Prefectural University of Medicine, is ready to enroll patients in this study. The Phase III study will be conducted at five clinical sites in Japan including University Hospital, Kyoto Prefectural University of Medicine. Each clinical site will begin screening patients subsequently once contracts and other preparations are all set. The Phase III study has been supported by the Japan Agency for Medical Research and Development(AMED) as its CiCLE program (Project title: Clinical development of recombinant HGF protein for thetreatment of refractory fibrosis).Reported Earnings • Nov 16Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)Full year 2022 results: JP¥68.16 loss per share. Revenue: JP¥391.0m (up 35% from FY 2021). Net loss: JP¥331.0m (loss widened 10.0% from FY 2021).お知らせ • Nov 16Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director & GM of Business Administration Department Koichi Murakami was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Oct 24Kringle Pharma, Inc. Submits Clinical Trial ApplicationKringle Pharma, Inc. announced that the clinical trial application has successfully submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to initiate a Phase III study of recombinant human HGF (KP-100LI) in patients with vocal fold scar. HGF, hepatocyte growth factor, is an endogenous protein responsible for regeneration and repair of tissues and organs in the human body. Its therapeutic effects have been validated in animal models of various diseases. One of the multiple biological functions of HGF is its potent antifibrotic activity, and HGF is expected to be an effective therapeutic agent for various intractable fibrotic diseases. KRINGLE is focusing on vocal fold scar as a target indication of drug development for fibrotic diseases. The investigator-initiated Phase I/II study already completed, demonstrating the safety and efficacy of intracordal administration of HGF (Hirano et al. J Tissue Eng Regen Med. 2018). The upcoming pivotal Phase III study is designed as a multicenter, randomized, placebo-controlled, double-blind, parallel-group study to confirm the safety and efficacy of KP-100LI in patients with vocal fold scar. This study will be conducted at five clinical sites in Japan including University Hospital, Kyoto Prefectural University of Medicine. The Phase III study has been supported by the Japan Agency for Medical Research and Development (AMED) as its CiCLE program (Project title: Clinical development of recombinant HGF protein for the treatment of refractory fibrosis).お知らせ • Sep 10Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio UniversityKringle Pharma, Inc. announced that it has jointly filed a patent application with Keio University on the combination use of recombinant human hepatocyte growth factor (HGF) with human induced pluripotent stem cell-derived neural stem/progenitor cell (hiPSC-NS/PC) as an effective treatment for spinal cord injury. The company has continued collaborative research with Professors Hideyuki Okano and Masaya Nakamura at Keio University School of Medicine since 2021, aiming to create novel therapies for spinal cord injury. As a result of this joint research, KRINGLE and Keio University already filed a patent application in March 2022, based on the improvement of functional recovery in the animal model of chronic complete spinal cord injury by transplanting hiPSC-NS/PC with the scaffold-mediated delivery of HGF. Further in the joint research, HGF administration in the acute phase, followed by transplantation of hiPSC-NS/PC in the sub-acute phase, significantly improved motor function in the animal model of severe spinal cord injury compared to each single treatment group, leading to the second patent application jointly filed by KRINGLE and Keio University. Currently, HGF monotherapy in acute spinal cord injury is being tested in a Phase III clinical trial by KRINGLE, and hiPSC-NS/PC transplantation in the sub-acute phase is ongoing in clinical research by Keio University, respectively. Therefore, a next-generation regenerative therapy combining the HGF and iPS cell technologies is expected to be put into clinical use before long for the treatment of acute and sub-acute spinal cord injuries. The preclinical results will be presented by Keio University School of Medicine during the 57th Annual Meeting of the Japan Medical Society of Spinal Cord Lesion.お知らせ • Sep 01Kringle Pharma, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022Kringle Pharma, Inc. announced that they will report fiscal year 2022 results on Nov 14, 2022お知らせ • Aug 27Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022Kringle Pharma, Inc. provided earnings guidance for the year ending September 30, 2022. For the year, the company expects net sales of JPY 357 million, operating loss of JPY 497 million, loss of JPY 421 million or JPY 89.24 per basic share.Reported Earnings • Aug 14Third quarter 2022 earnings released: EPS: JP¥2.57 (vs JP¥12.50 loss in 3Q 2021)Third quarter 2022 results: EPS: JP¥2.57 (up from JP¥12.50 loss in 3Q 2021). Revenue: JP¥85.0m (flat on 3Q 2021). Net income: JP¥13.0m (up JP¥67.0m from 3Q 2021). Profit margin: 15% (up from null in 3Q 2021).お知らせ • Aug 13Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALSKringle Pharma, Inc. announces that it has received the results of the investigator-initiated phase 2 clinical study evaluating its recombinant human HGF for the treatment of amyotrophic lateral sclerosis from Tohoku University, located in Miyagi, Japan. The study was a randomized, double-blind, placebo-controlled, phase 2 clinical study to evaluate the efficacy and safety of KP-100IT in a total of 46 ALS patients with Japan ALS Severity Classification of Grade 1 or 2, within 30 months of onset of the disease. KP-100IT or placebo was administered intrathecally once every two weeks, and the change in ALSFRS-R score at the 24-week treatment period was evaluated as a primary endpoint. As a result, there was no statistically significant difference between the KP-100IT group and the placebo group. No statistically significant differences were observed in the pre-specified secondary endpoints between the two groups. On the other hand, in the KP- 100IT administered group, slowing of the disease progression was observed in some cases and further detailed analysis is required to interpret the results of this study. Regarding safety, the incidence of adverse events was similar between the KP-100IT and placebo groups, confirming that the intrathecal administration of KP-100IT was well-tolerated. KRINGLE will discuss with Tohoku University to determine the potential next step of development based on the results of further detailed analysis of the study.お知らせ • Jun 01Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2022. For the full year, the company expected net sales to be JPY 355 million, Operating loss to be JPY 1,357 million, Loss to be JPY 1,297 million and Basic loss per share to be JPY 299.22.Reported Earnings • May 17Second quarter 2022 earnings released: JP¥40.79 loss per share (vs JP¥12.50 loss in 2Q 2021)Second quarter 2022 results: JP¥40.79 loss per share (down from JP¥12.50 loss in 2Q 2021). Net loss: JP¥190.0m (loss widened 252% from 2Q 2021).お知らせ • May 14Kringle Pharma, Inc. Provides an Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord InjuryKringle Pharma, Inc. provides an update on Phase 3 clinical trial of KP-100IT, the intrathecal formulation of recombinant human HGF, in patients with acute spinal cord injury. This trial is currently ongoing at five clinical trial sites in Japan, with the estimated enrollment of 25 participants. Since the start of the trial in July 2020, patient enrollment was progressing approximately at the expected pace until recently. Due to the impact of the latest re-expansion of COVID-19 in Japan, however, the enrollment pace is slowing down and the enrollment has not reached the target number as of May 13, 2022. Under those uncertain circumstances of the COVID-19 pandemic, KRINGLE has submitted the notification to PMDA (Pharmaceuticals and Medical Devices Agency) to extend the study period for six months. KRINGLE continues close collaboration with the clinical trial sites aiming to complete the patient enrollment in the second half of 2022, expecting the last patient out in the first half of 2023. HGF was originally discovered as an endogenous mitogen for mature hepatocytes. Subsequent studies demonstrated that HGF exerts multiple biological functions based on its mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic, and angiogenic activities, and facilitates regeneration and protection of a wide variety of organs. HGF exerts neurotrophic effects and enhances neurite outgrowth, and the therapeutic effects of HGF on spinal cord injury and ALS have been demonstrated in animal models by Professors Hideyuki Okano and Masaya Nakamura at Keio University School of Medicine and Professor Masashi Aoki at Tohoku University School of Medicine, respectively. Expectations for HGF as a novel therapeutic agent are increasing for such intractable neuronal diseases.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director & GM of Business Administration Department Koichi Murakami was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 28Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2022. For the period, the company expects net sales to be JPY 355 million, operating loss to be JPY 1,357 million, loss to be JPY 1,297 million and basic loss per share to be JPY 299.22.Reported Earnings • Feb 16First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: JP¥29.02 loss per share. Revenue: JP¥13.0m (down 97% from 1Q 2021). Net loss: JP¥129.0m (down 358% from profit in 1Q 2021). Revenue was in line with analyst estimates.Reported Earnings • Dec 19Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥72.51 loss per share (up from JP¥2,119 loss in FY 2020). Revenue: JP¥289.8m (down 38% from FY 2020). Net loss: JP¥301.2m (loss widened 157% from FY 2020). Revenue was in line with analyst estimates.お知らせ • Dec 17Kringle Pharma, Inc. Provides Earnings Forecast for the Fiscal Year Ending September 30, 2022Kringle Pharma, Inc. provided earnings forecast for the fiscal year ending September 30, 2022. For the year, the company expects net sales of YEN 355 million, operating loss of YEN 1,357 million, net loss of YEN 1,297 million and loss per basic share of YEN 299.22.お知らせ • Dec 09Kringle Pharma, Inc Announces Last Patient Out in Phase 2 Study of Kp-100It for the Treatment of AlsKringle Pharma, Inc. announced that the last patient has now completed the treatment and follow-up in the randomized, double-blind, placebo-controlled Phase 2 study of KP-100IT in ALS. The study outline is registered in the UMIN Clinical Trials Registry with the ID No. UMIN000022050. KP-100IT, the intrathecal formulation of recombinant human hepatocyte growth factor, is a novel investigational drug that has neurotrophic activities in the central nervous system. KRINGLE successfully completed open-label, dose-escalating Phase 1 study in ALS patients and confirmed safety and pharmacokinetics profiles of the intrathecal administration of KP-100IT. These clinical results werepublished in The Journal of Clinical Pharmacology 2019, 59(5) 677687. Following the Phase 1 study, an investigator-initiated Phase 2 study was started by Professor Masashi Aoki, Department of Neurology in Tohoku University School of Medicine, on the basis of collaboration between KRINGLE and Tohoku University. HGF was originally discovered as an endogenous mitogen for mature hepatocytes. Subsequent studies demonstrated that HGF exerts multiple biological functions based on its mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic and angiogenic activities, and facilitates regeneration and protection of a wide variety of organs including not only liver, but also kidneys, heart, lungs, nerve tissues and skin. Therapeutic effects of HGF administration in model animals of intractable diseases have been reported in many scientific papers, and expectations for HGF as a novel therapeutic agent for intractable diseases are increasing.お知らせ • Aug 21Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2021Kringle Pharma, Inc. provided earnings guidance for the Fiscal Year Ending September 30, 2021. For the year, the company expects net sales of JPY 227 million. Operating loss was JPY 388 million. Ordinary loss was JPY 328 million. Loss was JPY 330 million. Basic loss per share were JPY 80.67.お知らせ • Mar 05Kringle Pharma, Inc. to Report Q2, 2021 Results on May 14, 2021Kringle Pharma, Inc. announced that they will report Q2, 2021 results on May 14, 2021お知らせ • Dec 30Kringle Pharma, Inc. to Report Q1, 2021 Results on Feb 12, 2021Kringle Pharma, Inc. announced that they will report Q1, 2021 results on Feb 12, 2021お知らせ • Dec 29Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million.Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 580,000 Price\Range: ¥1000 Discount Per Security: ¥80 Transaction Features: Sponsor Backed Offering株主還元4884JP BiotechsJP 市場7D-10.3%-5.6%1.9%1Y-55.3%-22.6%41.5%株主還元を見る業界別リターン: 4884過去 1 年間で-22.6 % の収益を上げたJP Biotechs業界を下回りました。リターン対市場: 4884は、過去 1 年間で41.5 % のリターンを上げたJP市場を下回りました。価格変動Is 4884's price volatile compared to industry and market?4884 volatility4884 Average Weekly Movement10.5%Biotechs Industry Average Movement9.3%Market Average Movement4.9%10% most volatile stocks in JP Market9.6%10% least volatile stocks in JP Market2.5%安定した株価: 4884の株価は、 JP市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 4884の weekly volatility ( 10% ) は過去 1 年間安定していますが、依然としてJPの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200117Kiichi Adachiwww.kringle-pharma.comクリングルファーマ株式会社は日本で難治性疾患治療薬の研究開発を行っている。同社は急性脊髄損傷、筋萎縮性側索硬化症、声帯瘢痕、急性腎障害の治療薬としてHGF製剤を開発している。クリングルファーマは2001年に法人化され、日本の北に本社を置いている。もっと見るKringle Pharma, Inc. 基礎のまとめKringle Pharma の収益と売上を時価総額と比較するとどうか。4884 基礎統計学時価総額JP¥2.89b収益（TTM）-JP¥920.00m売上高(TTM)JP¥73.00m39.6xP/Sレシオ-3.1xPER（株価収益率4884 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4884 損益計算書（TTM）収益JP¥73.00m売上原価JP¥0売上総利益JP¥73.00mその他の費用JP¥993.00m収益-JP¥920.00m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-125.19グロス・マージン100.00%純利益率-1,260.27%有利子負債／自己資本比率0%4884 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 12:31終値2026/05/29 00:00収益2026/03/31年間収益2025/09/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kringle Pharma, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Kyoichiro ShigemuraNomura Securities Co. Ltd.
Reported Earnings • May 13Second quarter 2026 earnings released: JP¥42.92 loss per share (vs JP¥43.84 loss in 2Q 2025)Second quarter 2026 results: JP¥42.92 loss per share. Net loss: JP¥314.2m (loss widened 5.0% from 2Q 2025).
New Risk • Apr 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥755m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥755m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (JP¥73m revenue, or US$457k). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (JP¥3.70b market cap, or US$23.3m).
分析記事 • Apr 01Is Kringle Pharma (TSE:4884) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
New Risk • Feb 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥755m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥755m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (JP¥73m revenue, or US$474k). Minor Risk Market cap is less than US$100m (JP¥2.96b market cap, or US$19.3m).
Reported Earnings • Feb 10First quarter 2026 earnings released: JP¥28.08 loss per share (vs JP¥31.23 loss in 1Q 2025)First quarter 2026 results: JP¥28.08 loss per share (improved from JP¥31.23 loss in 1Q 2025). Net loss: JP¥201.0m (loss narrowed 5.5% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Dec 25Full year 2025 earnings released: JP¥134 loss per share (vs JP¥118 loss in FY 2024)Full year 2025 results: JP¥134 loss per share (further deteriorated from JP¥118 loss in FY 2024). Net loss: JP¥916.0m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 13Second quarter 2026 earnings released: JP¥42.92 loss per share (vs JP¥43.84 loss in 2Q 2025)Second quarter 2026 results: JP¥42.92 loss per share. Net loss: JP¥314.2m (loss widened 5.0% from 2Q 2025).
New Risk • Apr 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥755m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥755m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (JP¥73m revenue, or US$457k). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (JP¥3.70b market cap, or US$23.3m).
分析記事 • Apr 01Is Kringle Pharma (TSE:4884) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
New Risk • Feb 12New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -JP¥755m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥755m free cash flow). Earnings have declined by 28% per year over the past 5 years. Revenue is less than US$1m (JP¥73m revenue, or US$474k). Minor Risk Market cap is less than US$100m (JP¥2.96b market cap, or US$19.3m).
Reported Earnings • Feb 10First quarter 2026 earnings released: JP¥28.08 loss per share (vs JP¥31.23 loss in 1Q 2025)First quarter 2026 results: JP¥28.08 loss per share (improved from JP¥31.23 loss in 1Q 2025). Net loss: JP¥201.0m (loss narrowed 5.5% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Dec 25Full year 2025 earnings released: JP¥134 loss per share (vs JP¥118 loss in FY 2024)Full year 2025 results: JP¥134 loss per share (further deteriorated from JP¥118 loss in FY 2024). Net loss: JP¥916.0m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
お知らせ • Dec 02+ 1 more updateKringle Pharma, Inc. to Report Q1, 2026 Results on Feb 09, 2026Kringle Pharma, Inc. announced that they will report Q1, 2026 results on Feb 09, 2026
Reported Earnings • Nov 15Full year 2025 earnings released: JP¥134 loss per share (vs JP¥118 loss in FY 2024)Full year 2025 results: JP¥134 loss per share (further deteriorated from JP¥118 loss in FY 2024). Net loss: JP¥916.0m (loss widened 21% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 12Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2025Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2025.
お知らせ • Aug 29Kringle Pharma, Inc. to Report Fiscal Year 2025 Results on Nov 12, 2025Kringle Pharma, Inc. announced that they will report fiscal year 2025 results on Nov 12, 2025
Reported Earnings • Aug 10Third quarter 2025 earnings released: JP¥33.20 loss per share (vs JP¥22.96 loss in 3Q 2024)Third quarter 2025 results: JP¥33.20 loss per share (further deteriorated from JP¥22.96 loss in 3Q 2024). Net loss: JP¥227.0m (loss widened 49% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 02Kringle Pharma, Inc. announced that it has received ¥1.003 million in funding from Evolution Capital Management LLCOn August 1, 2025, Kringle Pharma, Inc. closed the transaction.
お知らせ • Jun 27Kringle Pharma, Inc. to Report Q3, 2025 Results on Aug 08, 2025Kringle Pharma, Inc. announced that they will report Q3, 2025 results on Aug 08, 2025
New Risk • Jun 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.8% average weekly change). Earnings have declined by 35% per year over the past 5 years. Revenue is less than US$1m (JP¥72m revenue, or US$496k). Minor Risk Market cap is less than US$100m (JP¥6.89b market cap, or US$47.5m).
Reported Earnings • May 14Second quarter 2025 earnings released: JP¥43.84 loss per share (vs JP¥30.66 loss in 2Q 2024)Second quarter 2025 results: JP¥43.84 loss per share (further deteriorated from JP¥30.66 loss in 2Q 2024). Net loss: JP¥299.3m (loss widened 52% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 08First quarter 2025 earnings released: JP¥31.13 loss per share (vs JP¥29.45 loss in 1Q 2024)First quarter 2025 results: JP¥31.13 loss per share (further deteriorated from JP¥29.45 loss in 1Q 2024). Net loss: JP¥212.0m (loss widened 25% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings.
New Risk • Jan 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (JP¥80m revenue, or US$507k). Minor Risks Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (JP¥6.92b market cap, or US$43.9m).
お知らせ • Jan 03+ 1 more updateKringle Pharma, Inc. to Report Q1, 2025 Results on Feb 07, 2025Kringle Pharma, Inc. announced that they will report Q1, 2025 results on Feb 07, 2025
Reported Earnings • Dec 28Full year 2024 earnings released: JP¥118 loss per share (vs JP¥158 loss in FY 2023)Full year 2024 results: JP¥118 loss per share (improved from JP¥158 loss in FY 2023). Net loss: JP¥756.0m (loss narrowed 12% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
お知らせ • Nov 26Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2025Kringle Pharma, Inc. provided Non-consolidated earnings guidance for the fiscal year ending September 30, 2025. For the year, the company expects net sales of JPY 272 million, operating loss of JPY 1,379 million, loss of JPY 1,380 million and basic loss per share of JPY 202.7.
分析記事 • Nov 25We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
お知らせ • Nov 13Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024Kringle Pharma, Inc., Annual General Meeting, Dec 20, 2024.
お知らせ • Aug 29Kringle Pharma, Inc. to Report Fiscal Year 2024 Results on Nov 13, 2024Kringle Pharma, Inc. announced that they will report fiscal year 2024 results on Nov 13, 2024
お知らせ • Aug 22Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024Kringle Pharma, Inc. provided Non-consolidated earnings guidance for the fiscal year ending September 30, 2024. For the year, the company expects net sales of JPY 79 million, operating loss of JPY 1,003 million, loss of JPY 942 million and basic loss per share of JPY 147.23.
分析記事 • Jun 15Here's Why We're Not Too Worried About Kringle Pharma's (TSE:4884) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
Reported Earnings • May 17Second quarter 2024 earnings released: JP¥30.66 loss per share (vs JP¥29.35 loss in 2Q 2023)Second quarter 2024 results: JP¥30.66 loss per share (further deteriorated from JP¥29.35 loss in 2Q 2023). Net loss: JP¥197.0m (loss widened 25% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
分析記事 • Mar 02We Think Kringle Pharma (TSE:4884) Can Afford To Drive Business GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Reported Earnings • Feb 11First quarter 2024 earnings released: JP¥29.45 loss per share (vs JP¥29.18 loss in 1Q 2023)First quarter 2024 results: JP¥29.45 loss per share (further deteriorated from JP¥29.18 loss in 1Q 2023). Net loss: JP¥169.0m (loss widened 7.6% from 1Q 2023).
お知らせ • Nov 29Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2024. For the year, the company expects net sales of JPY 272 million, operating loss of JPY 1,133 million, loss of JPY 1,109 million and basic loss per share of JPY 200.86.
お知らせ • Nov 27+ 2 more updatesKringle Pharma, Inc. to Report Q1, 2024 Results on Feb 09, 2024Kringle Pharma, Inc. announced that they will report Q1, 2024 results on Feb 09, 2024
Reported Earnings • Nov 17Full year 2023 earnings released: JP¥158 loss per share (vs JP¥68.16 loss in FY 2022)Full year 2023 results: JP¥158 loss per share (further deteriorated from JP¥68.16 loss in FY 2022). Net loss: JP¥854.0m (loss widened 158% from FY 2022).
New Risk • Oct 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Revenue is less than US$5m (JP¥330m revenue, or US$2.2m). Market cap is less than US$100m (JP¥3.69b market cap, or US$24.6m).
お知らせ • Sep 02Kringle Pharma, Inc. to Report Fiscal Year 2023 Results on Nov 13, 2023Kringle Pharma, Inc. announced that they will report fiscal year 2023 results on Nov 13, 2023
お知らせ • Aug 31Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2023. For the year, the company expects net sales of JPY 68 million, operating loss of JPY 993 million, loss of JPY 955 million and basic loss per share of JPY 177.35.
Reported Earnings • Aug 16Third quarter 2023 earnings released: JP¥48.79 loss per share (vs JP¥2.57 profit in 3Q 2022)Third quarter 2023 results: JP¥48.79 loss per share (down from JP¥2.57 profit in 3Q 2022). Revenue: JP¥17.0m (down 80% from 3Q 2022). Net loss: JP¥263.0m (down JP¥276.0m from profit in 3Q 2022).
New Risk • Jul 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.7% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 21% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Shareholders have been diluted in the past year (3.7% increase in shares outstanding). Revenue is less than US$5m (JP¥398m revenue, or US$2.8m). Market cap is less than US$100m (JP¥4.61b market cap, or US$32.5m).
お知らせ • May 30Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2023. For the year, the company expects net sales of JPY 68 million, operating loss of JPY 993 million, loss of JPY 955 million and basic loss per share of JPY 177.44.
Reported Earnings • May 19First half 2023 earnings released: JP¥58.52 loss per share (vs JP¥70.08 loss in 1H 2022)First half 2023 results: JP¥58.52 loss per share (improved from JP¥70.08 loss in 1H 2022). Revenue: JP¥34.0m (up 26% from 1H 2022). Net loss: JP¥315.0m (loss narrowed 1.3% from 1H 2022).
Reported Earnings • Feb 12First quarter 2023 earnings released: JP¥29.18 loss per share (vs JP¥29.02 loss in 1Q 2022)First quarter 2023 results: JP¥29.18 loss per share (further deteriorated from JP¥29.02 loss in 1Q 2022). Revenue: JP¥17.0m (up 31% from 1Q 2022). Net loss: JP¥157.0m (loss widened 22% from 1Q 2022).
お知らせ • Jan 17Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold ScarKringle Pharma, Inc. announced that the first patient was enrolled in a placebo-controlled, double-blind Phase III study to evaluate the efficacy and safety of KP-100LI, the intracordal formulation containing recombinant human HGF, administered in patients with vocal fold scar. The first patient was screened and successfully enrolled for the study at University Hospital, Kyoto Prefectural University of Medicine. As announced in the company news release dated November 24, 2022, the study will be conducted at the five clinical trial sites across Japan including University Hospital, Kyoto Prefectural University of Medicine. Patient enrollment will subsequently start at the other four clinical sites as soon as the contracts and all preparations are completed. The Phase III study has been supported by the Japan Agency for Medical Research and Development (AMED) as its CiCLE program (Project title: Clinical development of recombinant HGF protein for the treatment of refractory fibrosis).
お知らせ • Jan 13Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord InjuryKringle Pharma, Inc. provided an update on Phase 3 clinical trial of KP-100IT, the intrathecal formulation of recombinant human HGF, in patients with acute spinal cord injury. KRINGLE was previously expecting to complete patient enrollment by the end of 2022. As of 13 January 2023, however,although more than 90% of the target subjects has been recruited, patient enrollment has not been completed yet primarily due to the prolonged impact of COVID-19 pandemic. KRINGLE continues to enroll patients until it reaches the target number, in close cooperation with the clinical trial sites in order to complete the study as soon as possible. HGF was originally discovered as an endogenous mitogen for mature hepatocytes. Subsequent studiesdemonstrated that HGF exerts multiple biological functions based on its mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic, and angiogenic activities, and facilitates regeneration and protection of a wide variety of organs. HGF exerts neurotrophic effects and enhances neurite outgrowth, and the therapeutic effect of HGF on spinal cord injury has been demonstrated in animal models by Professors Hideyuki Okano and Masaya Nakamura at Keio University School of Medicine. Expectations for HGF as a novel therapeutic agent are increasing for the treatment of spinal cord injury. Spinal cord injury is caused by trauma, leading to a variety of paralytic or painful symptoms. In descending order of incidence, tripping over, traffic accidents and falls from height are the main causes of spinal damage. Recently, due to the rise in the elderly population, tripping over is becoming an increasingly common cause.
Reported Earnings • Dec 28Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)Full year 2022 results: JP¥68.16 loss per share. Revenue: JP¥391.0m (up 35% from FY 2021). Net loss: JP¥331.0m (loss widened 10.0% from FY 2021).
お知らせ • Dec 28+ 2 more updatesKringle Pharma, Inc. to Report Q1, 2023 Results on Feb 10, 2023Kringle Pharma, Inc. announced that they will report Q1, 2023 results on Feb 10, 2023
お知らせ • Dec 01Kringle Pharma, Inc. Provides Consolidated Earnings Guidance for Year Ending September 30, 2023Kringle Pharma, Inc. provided consolidated earnings guidance for year ending September 30, 2023 . For the period, the company expected net sales of JPY 68 million, operating loss of JPY 993 million, loss of parent of JPY 955 million, Basic loss per share of JPY 177.50 per basic share.
お知らせ • Nov 24Kringle Pharma, Inc. Announces Initiation of Phase III Study of HGF in Vocal Fold ScarKringle Pharma, Inc. announced the start of Phase III, a placebo-controlled, double-blind clinical study, to confirm the efficacy and safety of recombinant human HGF (KP-100LI) administered in patients with vocal fold scar. KRINGLE aims to develop and commercialize HGF as an innovative therapeutic agent for various fibrotic diseases, focusing on vocal fold scar as the initial target indication. KRINGLE already submitted a Phase III clinical trial application to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, as announced by the KRINGLE news release dated October 24, 2022. Since then, the review process by PMDA was completed and the regulatory clearance was obtained to initiate the Phase III study. KRINGLE and Kyoto Prefectural Public University Corporation (Chairman: Akihiro Kinda) have signed a clinical trial agreement for the Phase III study, and University Hospital, Kyoto Prefectural University of Medicine, is ready to enroll patients in this study. The Phase III study will be conducted at five clinical sites in Japan including University Hospital, Kyoto Prefectural University of Medicine. Each clinical site will begin screening patients subsequently once contracts and other preparations are all set. The Phase III study has been supported by the Japan Agency for Medical Research and Development(AMED) as its CiCLE program (Project title: Clinical development of recombinant HGF protein for thetreatment of refractory fibrosis).
Reported Earnings • Nov 16Full year 2022 earnings released: JP¥68.16 loss per share (vs JP¥72.47 loss in FY 2021)Full year 2022 results: JP¥68.16 loss per share. Revenue: JP¥391.0m (up 35% from FY 2021). Net loss: JP¥331.0m (loss widened 10.0% from FY 2021).
お知らせ • Nov 16Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022Kringle Pharma, Inc., Annual General Meeting, Dec 23, 2022.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director & GM of Business Administration Department Koichi Murakami was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Oct 24Kringle Pharma, Inc. Submits Clinical Trial ApplicationKringle Pharma, Inc. announced that the clinical trial application has successfully submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan to initiate a Phase III study of recombinant human HGF (KP-100LI) in patients with vocal fold scar. HGF, hepatocyte growth factor, is an endogenous protein responsible for regeneration and repair of tissues and organs in the human body. Its therapeutic effects have been validated in animal models of various diseases. One of the multiple biological functions of HGF is its potent antifibrotic activity, and HGF is expected to be an effective therapeutic agent for various intractable fibrotic diseases. KRINGLE is focusing on vocal fold scar as a target indication of drug development for fibrotic diseases. The investigator-initiated Phase I/II study already completed, demonstrating the safety and efficacy of intracordal administration of HGF (Hirano et al. J Tissue Eng Regen Med. 2018). The upcoming pivotal Phase III study is designed as a multicenter, randomized, placebo-controlled, double-blind, parallel-group study to confirm the safety and efficacy of KP-100LI in patients with vocal fold scar. This study will be conducted at five clinical sites in Japan including University Hospital, Kyoto Prefectural University of Medicine. The Phase III study has been supported by the Japan Agency for Medical Research and Development (AMED) as its CiCLE program (Project title: Clinical development of recombinant HGF protein for the treatment of refractory fibrosis).
お知らせ • Sep 10Kringle Pharma, Inc. Announces Jointly File A Patent Application with Keio UniversityKringle Pharma, Inc. announced that it has jointly filed a patent application with Keio University on the combination use of recombinant human hepatocyte growth factor (HGF) with human induced pluripotent stem cell-derived neural stem/progenitor cell (hiPSC-NS/PC) as an effective treatment for spinal cord injury. The company has continued collaborative research with Professors Hideyuki Okano and Masaya Nakamura at Keio University School of Medicine since 2021, aiming to create novel therapies for spinal cord injury. As a result of this joint research, KRINGLE and Keio University already filed a patent application in March 2022, based on the improvement of functional recovery in the animal model of chronic complete spinal cord injury by transplanting hiPSC-NS/PC with the scaffold-mediated delivery of HGF. Further in the joint research, HGF administration in the acute phase, followed by transplantation of hiPSC-NS/PC in the sub-acute phase, significantly improved motor function in the animal model of severe spinal cord injury compared to each single treatment group, leading to the second patent application jointly filed by KRINGLE and Keio University. Currently, HGF monotherapy in acute spinal cord injury is being tested in a Phase III clinical trial by KRINGLE, and hiPSC-NS/PC transplantation in the sub-acute phase is ongoing in clinical research by Keio University, respectively. Therefore, a next-generation regenerative therapy combining the HGF and iPS cell technologies is expected to be put into clinical use before long for the treatment of acute and sub-acute spinal cord injuries. The preclinical results will be presented by Keio University School of Medicine during the 57th Annual Meeting of the Japan Medical Society of Spinal Cord Lesion.
お知らせ • Sep 01Kringle Pharma, Inc. to Report Fiscal Year 2022 Results on Nov 14, 2022Kringle Pharma, Inc. announced that they will report fiscal year 2022 results on Nov 14, 2022
お知らせ • Aug 27Kringle Pharma, Inc. Provides Earnings Guidance for the Year Ending September 30, 2022Kringle Pharma, Inc. provided earnings guidance for the year ending September 30, 2022. For the year, the company expects net sales of JPY 357 million, operating loss of JPY 497 million, loss of JPY 421 million or JPY 89.24 per basic share.
Reported Earnings • Aug 14Third quarter 2022 earnings released: EPS: JP¥2.57 (vs JP¥12.50 loss in 3Q 2021)Third quarter 2022 results: EPS: JP¥2.57 (up from JP¥12.50 loss in 3Q 2021). Revenue: JP¥85.0m (flat on 3Q 2021). Net income: JP¥13.0m (up JP¥67.0m from 3Q 2021). Profit margin: 15% (up from null in 3Q 2021).
お知らせ • Aug 13Kringle Pharma, Inc. Updates on the Investigator-initiated Phase 2 Study in Patients with ALSKringle Pharma, Inc. announces that it has received the results of the investigator-initiated phase 2 clinical study evaluating its recombinant human HGF for the treatment of amyotrophic lateral sclerosis from Tohoku University, located in Miyagi, Japan. The study was a randomized, double-blind, placebo-controlled, phase 2 clinical study to evaluate the efficacy and safety of KP-100IT in a total of 46 ALS patients with Japan ALS Severity Classification of Grade 1 or 2, within 30 months of onset of the disease. KP-100IT or placebo was administered intrathecally once every two weeks, and the change in ALSFRS-R score at the 24-week treatment period was evaluated as a primary endpoint. As a result, there was no statistically significant difference between the KP-100IT group and the placebo group. No statistically significant differences were observed in the pre-specified secondary endpoints between the two groups. On the other hand, in the KP- 100IT administered group, slowing of the disease progression was observed in some cases and further detailed analysis is required to interpret the results of this study. Regarding safety, the incidence of adverse events was similar between the KP-100IT and placebo groups, confirming that the intrathecal administration of KP-100IT was well-tolerated. KRINGLE will discuss with Tohoku University to determine the potential next step of development based on the results of further detailed analysis of the study.
お知らせ • Jun 01Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2022. For the full year, the company expected net sales to be JPY 355 million, Operating loss to be JPY 1,357 million, Loss to be JPY 1,297 million and Basic loss per share to be JPY 299.22.
Reported Earnings • May 17Second quarter 2022 earnings released: JP¥40.79 loss per share (vs JP¥12.50 loss in 2Q 2021)Second quarter 2022 results: JP¥40.79 loss per share (down from JP¥12.50 loss in 2Q 2021). Net loss: JP¥190.0m (loss widened 252% from 2Q 2021).
お知らせ • May 14Kringle Pharma, Inc. Provides an Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord InjuryKringle Pharma, Inc. provides an update on Phase 3 clinical trial of KP-100IT, the intrathecal formulation of recombinant human HGF, in patients with acute spinal cord injury. This trial is currently ongoing at five clinical trial sites in Japan, with the estimated enrollment of 25 participants. Since the start of the trial in July 2020, patient enrollment was progressing approximately at the expected pace until recently. Due to the impact of the latest re-expansion of COVID-19 in Japan, however, the enrollment pace is slowing down and the enrollment has not reached the target number as of May 13, 2022. Under those uncertain circumstances of the COVID-19 pandemic, KRINGLE has submitted the notification to PMDA (Pharmaceuticals and Medical Devices Agency) to extend the study period for six months. KRINGLE continues close collaboration with the clinical trial sites aiming to complete the patient enrollment in the second half of 2022, expecting the last patient out in the first half of 2023. HGF was originally discovered as an endogenous mitogen for mature hepatocytes. Subsequent studies demonstrated that HGF exerts multiple biological functions based on its mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic, and angiogenic activities, and facilitates regeneration and protection of a wide variety of organs. HGF exerts neurotrophic effects and enhances neurite outgrowth, and the therapeutic effects of HGF on spinal cord injury and ALS have been demonstrated in animal models by Professors Hideyuki Okano and Masaya Nakamura at Keio University School of Medicine and Professor Masashi Aoki at Tohoku University School of Medicine, respectively. Expectations for HGF as a novel therapeutic agent are increasing for such intractable neuronal diseases.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director & GM of Business Administration Department Koichi Murakami was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 28Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2022Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2022. For the period, the company expects net sales to be JPY 355 million, operating loss to be JPY 1,357 million, loss to be JPY 1,297 million and basic loss per share to be JPY 299.22.
Reported Earnings • Feb 16First quarter 2022 earnings: Revenues and EPS in line with analyst expectationsFirst quarter 2022 results: JP¥29.02 loss per share. Revenue: JP¥13.0m (down 97% from 1Q 2021). Net loss: JP¥129.0m (down 358% from profit in 1Q 2021). Revenue was in line with analyst estimates.
Reported Earnings • Dec 19Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: JP¥72.51 loss per share (up from JP¥2,119 loss in FY 2020). Revenue: JP¥289.8m (down 38% from FY 2020). Net loss: JP¥301.2m (loss widened 157% from FY 2020). Revenue was in line with analyst estimates.
お知らせ • Dec 17Kringle Pharma, Inc. Provides Earnings Forecast for the Fiscal Year Ending September 30, 2022Kringle Pharma, Inc. provided earnings forecast for the fiscal year ending September 30, 2022. For the year, the company expects net sales of YEN 355 million, operating loss of YEN 1,357 million, net loss of YEN 1,297 million and loss per basic share of YEN 299.22.
お知らせ • Dec 09Kringle Pharma, Inc Announces Last Patient Out in Phase 2 Study of Kp-100It for the Treatment of AlsKringle Pharma, Inc. announced that the last patient has now completed the treatment and follow-up in the randomized, double-blind, placebo-controlled Phase 2 study of KP-100IT in ALS. The study outline is registered in the UMIN Clinical Trials Registry with the ID No. UMIN000022050. KP-100IT, the intrathecal formulation of recombinant human hepatocyte growth factor, is a novel investigational drug that has neurotrophic activities in the central nervous system. KRINGLE successfully completed open-label, dose-escalating Phase 1 study in ALS patients and confirmed safety and pharmacokinetics profiles of the intrathecal administration of KP-100IT. These clinical results werepublished in The Journal of Clinical Pharmacology 2019, 59(5) 677687. Following the Phase 1 study, an investigator-initiated Phase 2 study was started by Professor Masashi Aoki, Department of Neurology in Tohoku University School of Medicine, on the basis of collaboration between KRINGLE and Tohoku University. HGF was originally discovered as an endogenous mitogen for mature hepatocytes. Subsequent studies demonstrated that HGF exerts multiple biological functions based on its mitogenic, motogenic, anti-apoptotic, morphogenic, anti-fibrotic and angiogenic activities, and facilitates regeneration and protection of a wide variety of organs including not only liver, but also kidneys, heart, lungs, nerve tissues and skin. Therapeutic effects of HGF administration in model animals of intractable diseases have been reported in many scientific papers, and expectations for HGF as a novel therapeutic agent for intractable diseases are increasing.
お知らせ • Aug 21Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2021Kringle Pharma, Inc. provided earnings guidance for the Fiscal Year Ending September 30, 2021. For the year, the company expects net sales of JPY 227 million. Operating loss was JPY 388 million. Ordinary loss was JPY 328 million. Loss was JPY 330 million. Basic loss per share were JPY 80.67.
お知らせ • Mar 05Kringle Pharma, Inc. to Report Q2, 2021 Results on May 14, 2021Kringle Pharma, Inc. announced that they will report Q2, 2021 results on May 14, 2021
お知らせ • Dec 30Kringle Pharma, Inc. to Report Q1, 2021 Results on Feb 12, 2021Kringle Pharma, Inc. announced that they will report Q1, 2021 results on Feb 12, 2021
お知らせ • Dec 29Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million.Kringle Pharma, Inc. has completed an IPO in the amount of ¥580 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 580,000 Price\Range: ¥1000 Discount Per Security: ¥80 Transaction Features: Sponsor Backed Offering
